Analyst Ratings for Achillion Pharmaceuticals (ACHN) [Buys]
ACHN Rating Summary
ACHN Price Target Summary
- Highest: $20.00 (ThinkEquity)
- Lowest: $10.00 (JMP Securities)
- Average: $15.13
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$15.13 (+98%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/4/2013 | Baird | New Coverage | Outperform (N/A) |
17.00 (N/A) |
8.76 | 7.64 | -12.79% | Details |
| 9/19/2012 | Deutsche Bank » Updated 10/16/2012 |
New Coverage | Buy (N/A) |
17.00 (12.00) |
8.10 | 7.64 | -5.68% | Details |
| 9/19/2012 | BofA/Merrill Lynch | Upgrade | Buy (Underperform) |
N/A (N/A) |
8.10 | 7.64 | -5.68% | Details |
| 8/16/2012 | JMP Securities | Upgrade | Market Outperform (Market Perform) |
10.00 (N/A) |
5.90 | 7.64 | 29.49% | Details |
| 6/13/2012 | Maxim Group | New Coverage | Buy (N/A) |
12.00 (N/A) |
6.16 | 7.64 | 24.03% | Details |
| 4/17/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
N/A (N/A) |
8.77 | 7.64 | -12.88% | Details |
| 3/27/2012 | Wedbush | New Coverage | Outperform (N/A) |
13.00 (N/A) |
10.22 | 7.64 | -25.24% | Details |
| 11/29/2011 | Wells Fargo » Updated 11/12/2012 |
New Coverage | Outperform (N/A) |
N/A (N/A) |
5.95 | 7.64 | 28.4% | Details |
| 9/8/2011 | Piper Jaffray | New Coverage | Overweight (N/A) |
12.00 (N/A) |
5.72 | 7.64 | 33.57% | Details |
| 6/2/2011 | Brean Capital » Updated 4/23/2012 |
New Coverage | Buy (N/A) |
20.00 (N/A) |
7.39 | 7.64 | 3.38% | Details |
| 6/2/2011 | ThinkEquity » Updated 1/10/2012 |
New Coverage | Buy (N/A) |
20.00 (N/A) |
7.39 | 7.64 | 3.38% | Details |
| 5/26/2011 | William Blair | New Coverage | Outperform (N/A) |
N/A (N/A) |
6.09 | 7.64 | 25.45% | Details |
| 5/12/2011 | Roth Capital | New Coverage | Buy (N/A) |
N/A (N/A) |
5.10 | 7.64 | 49.8% | Details |
| 3/1/2011 | Leerink Swann | New Coverage | Outperform (N/A) |
N/A (N/A) |
5.85 | 7.64 | 30.6% | Details |
